$35.20
3.38% day before yesterday
Nasdaq, Jul 18, 10:00 pm CET
ISIN
US4131971040
Symbol
HRMY

Harmony Biosciences Holdings Target price 2025 - Analyst rating & recommendation

Harmony Biosciences Holdings Classifications & Recommendation:

Buy
87%
Hold
7%
Sell
7%

Harmony Biosciences Holdings Price Target

Target Price $49.47
Price $35.20
Potential
Number of Estimates 12
12 Analysts have issued a price target Harmony Biosciences Holdings 2026 . The average Harmony Biosciences Holdings target price is $49.47. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 15 analysts: 13 Analysts recommend Harmony Biosciences Holdings to buy, 1 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Harmony Biosciences Holdings stock has an average upside potential 2026 of . Most analysts recommend the Harmony Biosciences Holdings stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 714.73 860.04
22.80% 20.33%
EBITDA Margin 30.08% 36.07%
18.86% 19.91%
Net Margin 20.29% 22.33%
8.47% 10.07%

12 Analysts have issued a sales forecast Harmony Biosciences Holdings 2025 . The average Harmony Biosciences Holdings sales estimate is

$860m
Unlock
. This is
15.46% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$901m 20.97%
Unlock
, the lowest is
$810m 8.69%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $715m 22.80%
2025
$860m 20.33%
Unlock
2026
$1.0b 17.67%
Unlock
2027
$1.2b 15.61%
Unlock
2028
$1.4b 22.39%
Unlock
2029
$1.7b 17.53%
Unlock
2030
$1.7b 0.89%
Unlock
2031
$1.0b 39.99%
Unlock
2032
$954m 6.34%
Unlock

7 Analysts have issued an Harmony Biosciences Holdings EBITDA forecast 2025. The average Harmony Biosciences Holdings EBITDA estimate is

$310m
Unlock
. This is
41.76% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$345m 57.69%
Unlock
, the lowest is
$267m 22.12%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $215m 0.36%
2025
$310m 44.29%
Unlock
2026
$392m 26.49%
Unlock
2027
$463m 17.93%
Unlock
2028
$520m 12.32%
Unlock
2029
$637m 22.51%
Unlock
2030
$679m 6.70%
Unlock
2031
$333m 51.00%
Unlock
2032
$281m 15.56%
Unlock

EBITDA Margin

2024 30.08% 18.86%
2025
36.07% 19.91%
Unlock
2026
38.77% 7.49%
Unlock
2027
39.55% 2.01%
Unlock
2028
36.30% 8.22%
Unlock
2029
37.84% 4.24%
Unlock
2030
40.02% 5.76%
Unlock
2031
32.67% 18.37%
Unlock
2032
29.45% 9.86%
Unlock

11 Harmony Biosciences Holdings Analysts have issued a net profit forecast 2025. The average Harmony Biosciences Holdings net profit estimate is

$192m
Unlock
. This is
25.50% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$251m 63.90%
Unlock
, the lowest is
$123m 19.68%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $145m 12.40%
2025
$192m 32.42%
Unlock
2026
$247m 28.75%
Unlock
2027
$301m 21.72%
Unlock
2028
$532m 76.93%
Unlock
2029
$660m 23.94%
Unlock

Net Margin

2024 20.29% 8.47%
2025
22.33% 10.07%
Unlock
2026
24.43% 9.40%
Unlock
2027
25.72% 5.28%
Unlock
2028
37.18% 44.56%
Unlock
2029
39.21% 5.46%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 2.51 3.37
16.74% 34.26%
P/E 10.45
EV/Sales 1.97

11 Analysts have issued a Harmony Biosciences Holdings forecast for earnings per share. The average Harmony Biosciences Holdings EPS is

$3.37
Unlock
. This is
30.12% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$4.40 69.88%
Unlock
, the lowest is
$2.16 16.60%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $2.51 16.74%
2025
$3.37 34.26%
Unlock
2026
$4.34 28.78%
Unlock
2027
$5.28 21.66%
Unlock
2028
$9.34 76.89%
Unlock
2029
$11.58 23.98%
Unlock

P/E ratio

Current 13.59 19.87%
2025
10.45 23.11%
Unlock
2026
8.12 22.30%
Unlock
2027
6.67 17.86%
Unlock
2028
3.77 43.48%
Unlock
2029
3.04 19.36%
Unlock

Based on analysts' sales estimates for 2025, the Harmony Biosciences Holdings stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.27 15.30%
2025
1.97 13.41%
Unlock
2026
1.67 15.02%
Unlock
2027
1.44 13.50%
Unlock
2028
1.18 18.30%
Unlock
2029
1.00 14.91%
Unlock
2030
1.00 0.89%
Unlock
2031
1.66 66.64%
Unlock
2032
1.77 6.76%
Unlock

P/S ratio

Current 2.71 7.17%
2025
2.35 13.39%
Unlock
2026
2.00 15.02%
Unlock
2027
1.73 13.51%
Unlock
2028
1.41 18.29%
Unlock
2029
1.20 14.92%
Unlock
2030
1.19 0.88%
Unlock
2031
1.98 66.64%
Unlock
2032
2.12 6.77%
Unlock

Current Harmony Biosciences Holdings Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Deutsche Bank
Locked
Locked
Locked Jul 10 2025
Mizuho
Locked
Locked
Locked May 15 2025
Needham
Locked
Locked
Locked May 07 2025
Needham
Locked
Locked
Locked May 06 2025
UBS
Locked
Locked
Locked Apr 28 2025
Needham
Locked
Locked
Locked Apr 10 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 08 2025
Analyst Rating Date
Locked
Deutsche Bank:
Locked
Locked
Jul 10 2025
Locked
Mizuho:
Locked
Locked
May 15 2025
Locked
Needham:
Locked
Locked
May 07 2025
Locked
Needham:
Locked
Locked
May 06 2025
Locked
UBS:
Locked
Locked
Apr 28 2025
Locked
Needham:
Locked
Locked
Apr 10 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 08 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today